13 recruiting, 3 completed, 2 active not recruiting. 8 Phase 2, 6 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 8 |
| Phase 1 | 6 | Completed 3, Active not recruiting 2, Recruiting 1 |
| Phase 3 | 4 | Recruiting 4 |
Follow LY3537031: new trials by email Literature Review of LY3537031 trials Research Report on LY3537031
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder Brenipatide, Placebo - Depressive Disorder, Major | Phase 3 | Recruiting | Eli Lilly and Company | 1000 | 2026-08-14 | 2026-11-03 |
| A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) Brenipatide, Placebo, Standard of Care - Pulmonary Disease, Chronic Obstructive | Phase 2 | Recruiting | Eli Lilly and Company | 606 | 2026-08-07 | 2026-11-05 |
| A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D) LY3537031, Placebo - Irritable Bowel Syndrome, Diarrhea | Phase 2 | Recruiting | Eli Lilly and Company | 531 | 2026-05-06 | 2026-11-04 |
| A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C) LY3537031, Placebo - Irritable Bowel Syndrome, Constipation | Phase 2 | Recruiting | Eli Lilly and Company | 342 | 2026-04-29 | 2026-11-05 |
| A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity Brenipatide, Placebo - Obesity, Overweight | Phase 1 | Active not recruiting | Eli Lilly and Company | 150 | 2026-03-18 | 2026-07-16 |
| A Study of Brenipatide in Participants With Opioid Use Disorder Brenipatide, Placebo, Buprenorphine - Opioid Use Disorder | Phase 2 | Recruiting | Eli Lilly and Company | 465 | 2026-02-13 | 2026-11-04 |
| A Study of Brenipatide in Adult Participants With Schizophrenia Brenipatide, Placebo - Schizophrenia | Phase 2 | Recruiting | Eli Lilly and Company | 450 | 2026-02-10 | 2026-10-07 |
| A Study of Brenipatide in Adult Participants With Major Depressive Disorder Brenipatide, Placebo - Depressive Disorder, Major | Phase 3 | Recruiting | Eli Lilly and Company | 1000 | 2026-02-09 | 2026-11-04 |
| A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1) Brenipatide, Placebo - Bipolar Disorder | Phase 2 | Recruiting | Eli Lilly and Company | 400 | 2025-11-24 | 2026-11-04 |
| A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse Brenipatide, Placebo - Smoking | Phase 2 | Recruiting | Eli Lilly and Company | 222 | 2025-11-03 | 2026-09-22 |
| A Study of How the Body Absorbs LY3537031 LY3537031 - Healthy | Phase 1 | Completed | Eli Lilly and Company | 47 | 2025-11-03 | 2026-07-23 |
| A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma Brenipatide, Placebo - Asthma | Phase 2 | Recruiting | Eli Lilly and Company | 531 | 2025-10-22 | 2026-11-05 |
| A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment LY3537031 - Healthy, Hepatic Insufficiency | Phase 1 | Recruiting | Eli Lilly and Company | 32 | 2025-10-20 | 2026-09-30 |
| A Study of Brenipatide in Participants With Alcohol Use Disorder LY3537031, Placebo - Alcohol Use Disorder | Phase 3 | Recruiting | Eli Lilly and Company | 1100 | 2025-10-16 | 2026-11-04 |
| A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder LY3537031, Placebo - Alcohol Use Disorder | Phase 3 | Recruiting | Eli Lilly and Company | 1100 | 2025-10-15 | 2026-10-07 |
| A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment LY3537031 - Renal Impairment, Healthy | Phase 1 | Completed | Eli Lilly and Company | 31 | 2025-09-18 | 2026-04-24 |
| A Study of LY3537031 in Overweight, Obese, and Healthy Participants LY3537031, Placebo - Overweight, Obesity | Phase 1 | Active not recruiting | Eli Lilly and Company | 302 | 2024-09-05 | 2026-09-30 |
| A Study of LY3537031 in Healthy Participants LY3537031, Placebo - Healthy | Phase 1 | Completed | Eli Lilly and Company | 40 | 2020-12-09 | 2021-06-21 |
Alcoholism (2) · Depression (2) · Depressive Disorder (2) · Depressive Disorder, Major (2) · Irritable Bowel Syndrome (2) · Mood Disorders (2) · Obesity (2) · Overweight (2) · Asthma (1) · Bipolar Disorder (1) · Bronchitis, Chronic (1) · Constipation (1) · Diarrhea (1) · Emphysema (1) · Hepatic Insufficiency (1)
United States (15) · Japan (12) · China (11) · United Kingdom (8) · Canada (7) · Germany (7) · Mexico (7) · Brazil (5) · Poland (5) · Puerto Rico (5) · South Korea (5) · Taiwan (5) · Argentina (4) · Belgium (4) · India (4)
2025 (7)